- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
Johnson and Johnson/Janssen announced their candidate COVID-19 vaccine has entered the third (final) phase of clinical trials. Interim results (not yet published) reportedly showed that the product's safety profile and immunogenicity after a single vaccination "were supportive of further development."
Unlike the other vaccines that are currently in this stage, this vaccine is being tested with only one dose. It can also be stored in regular refrigeration temperatures. Some other vaccine candidates need very cold storage. The trial will involve as many as 60,000 participants in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and the United States. These sites were chosen since they currently have high incidence of COVID-19, which will help researchers determine how protective the vaccine is. Results are not expected for at least two months.
Countering Misinformation & Disinformation: Practical Training for Organizations
Practical skills to detect, verify, and respond across an evolving information landscape
Additional data provided by
English
Japanese
